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Abstract
Purpose To summarize the physical principles, imaging method, available tools for and the clinical value of quantitative 
perfusion evaluation with cardiac PET as well as future aims in the field in a narrative review.
Results  Cardiac positron-emission tomography (PET) currently constitutes the reference standard for non-invasive quantita-
tive evaluation of myocardial blood flow. This added modality provides useful information beyond standard semi-quantitative 
myocardial perfusion evaluation. A description of how the different phases of PET studies are interpreted is provided, as 
well as a short depiction of the most commonly used radiotracers and the main characteristics affecting their clinical utility. 
The diagnostic and prognostic utility concerning myocardial perfusion quantified in absolute terms is discussed and the 
additional contribution of the increasingly spread hybrid equipment is summarized.
Conclusion PET myocardial perfusion represents an excellent noninvasive technique for the evaluation of known or suspected 
ischemic heart disease, and its clinical application should widen in the near future. The clinical value of PET quantitative 
perfusion is expected to improve patient outcomes and optimize therapeutic decisions, which constitute key elements for 
the future of cardiovascular medicine.
Keywords Positron-emission tomography · Coronary artery disease · Myocardial perfusion imaging · Myocardial blood 
flow
Introduction
Positron-emission tomography myocardial perfusion imag-
ing (PET MPI) has loomed and crystallized within nuclear 
medicine techniques during the last three decades due to 
its ability to assess myocardial blood flow (MBF) in abso-
lute terms. Currently, PET MPI represents the gold stand-
ard modality for this purpose. By fueling the enthusiasm 
of cardiovascular scientists and physicians, this approach 
in cardiac imaging has propelled the non-invasive assess-
ment of cardiac physiology and pathophysiology to a new 
state-of-the-art.
Translational research for MBF quantification has been 
an intense research topic. The results of such efforts have led 
to its complete integration into daily practice in a growing 
amount of selected centers around the world (e.g., Finland, 
The Netherlands and Sweden) as the intrinsic diagnostic and 
prognostic added value of the modality has been robustly 
demonstrated. The present review aims to summarize the 
evidence behind the increasingly suggested clinical impor-
tance of cardiac PET quantitative perfusion in the setting of 
diagnosis and prognosis of coronary artery disease (CAD). 
Additionally, the technique’s principles, methods and par-
ticularities, and future perspectives will be presented.
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PET technology in myocardial perfusion 
imaging
PET technology uses coincidence detection of pairs of 
high-energy photons that are emitted (γ-rays with an angle 
of 180° between them and energy of 511 keV) from the 
“annihilation” of an emitted positron with a free electron 
as shown in Fig. 1. These positrons arise from the decay of 
radiopharmaceuticals administered to the patient in order 
to track (patho)physiological processes.
The two photons are detected in opposite sides of the 
ring detectors embedded in the camera. Improved detec-
tors (LSO, LYSO or LGSO) are coupled to optimized elec-
tronics yield high peak count rates and currently, events 
can be detected in a 3D mode through the entire cardiac 
field-of-view and the hybrid composition of the scanners 
allows for the use of CT to create an attenuation map or 
transmission image for automatic attenuation losses and 
scatter correction [1].
Acquisition and reconstruction
Presently, “list-mode” acquisition is performed to recon-
struct static, dynamic and gated images with a single radi-
otracer injection. In such a modality, all of the acquisition 
measured coincidences and the time tags are saved in a file 
for retrospective processing.
Static data are traditionally reconstructed from the final 
frame (≈ 900 ms) obtained for visual and semi-quantitative 
interpretation (% uptake relative to a reference region, usu-
ally the one with the highest uptake). Further, myocardial 
perfusion absolute quantification is derived from the sequen-
tial dynamic first-pass images which, when paired to the 
EKG or respiratory gating, further permit evaluation of LV 
contractile function and even phase synchrony. 3D-mode 
acquisitions convey higher sensitivity and optimized cor-
rections. In turn, this facilitates reduction in injected doses 
and therefore optimization of dosimetry (see Dosimetry).
Methods for optimizing image reconstruction have been 
implemented including filtered-back projection and cur-
rently, the widely used iterative reconstruction approaches. 
Iterative reconstructions deliver images with reduced noise 
and enhanced myocardium contrast and resolution, with 
added improved temporal resolution. As such, due to sensi-
tivity to counts and the nature of the detection, PET scanning 
has proven superior image quality and therefore increased 
diagnostic accuracy over SPECT [2].
PET imaging protocols
PET MPI is generally conducted in a two-phase acquisition, 
i.e., during rest and during stress (either physical or pharma-
cological). However, it is also possible to conduct a three-
phase scan which incorporates cold pressor testing (CPT) 
through sympathetic stimulation. The total acquisition time 
will, therefore, depend on the number of performed phases, 
Fig. 1  PET technology 
principle. Diagram depicting 
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the stress-induction protocol, the length of the dynamic 
imaging (which depends upon the tracer) and the CT imag-
ing (in hybrid equipment). In average, a full rest–stress and 
CT acquisition can be performed in 30–40 min [3], a shorter 
time when compared to SPECT due to the half-life of the 
radiotracers.
Quantitative perfusion begins with a topogram acqui-
sition for patient positioning. Then, a CT transmission 
scan is acquired. Afterwards, the radiotracer is injected 
(25–50 mCi of 82Rb, 10–30 mCi of 15O-H2O or 10–20 mCi 
of 13N-ammonia) and the rest imaging acquisition is initiated 
simultaneously (5–6 min for 82Rb or 15O-H2O and 10 min for 
13N-ammonia) [4]. Then, stress is induced and a second dose 
of radiotracer is injected and the stress imaging acquisition 
is performed. The most common pharmacologic stressor is 
adenosine administered as a 4- to 6-min infusion of 140 µg/
Kg/min 2 or 3 min before the injection of the radiotracer. 
Regadenoson constitutes another option for pharmacological 
stress induction with a favorable profile specially in patients 
with COPD [5]. It is administered as a 0.4 mg bolus injected 
over 15–20 s and followed by a 10-ml saline flush before the 
injection of the radiotracer. However, its clinical use has not 
been widely spread yet.
With 15O-H2O and 82Rb, the second phase can be per-
formed without delay after the first study. However, with 
13N-ammonia the second study (stress or rest) is routinely 
delayed 30 min after the first study, to allow for radiotracer 
decay and the image acquisition is started a few seconds 
before the radiotracer injection. When a three-phase scan is 
performed, the CPT takes place after rest and before stress. 
CPT is evoked by submerging the patient’s hand in ice water 
60 s before and 60 s after the beginning of the acquisition 
and administration of the tracer acquisition [6].
Furthermore, hybrid equipment offer the possibility to 
acquire a CT angiography (usually before the PET acquisi-
tion; in some centers, such CCTA is used for pre-selection 
of patients who can benefit from PET) and coronary artery 
calcium measurement within the same imaging session. Fig-
ure 2 depicts example protocols for PET and PET/CT.
Clinical protocols have been suggested for new promis-
ing compounds such as 18F-flurpiridaz [7]. This fluorine-
18-based tracer extends the possibilities of perfusion imag-
ing implementation through a regional rather than on-site 
cyclotron due to its longer half-life (110 min). Moreover, 
18F-flurpiridaz would facilitate exercise testing in contrast 
to other commonly used tracers [8].
Dosimetry
Several current standards for PET MPI, such as 3D acquisi-
tion and state-of-the-art software, offer the possibility for 
reduced radiation doses. A full 82Rb 3D PET scan implies 
an exposure of ≈ 4.3 mSv, while for a single 13N-ammo-
nia 3D scan, the estimated the radiation dose is around 1, 
and 0.8 mSv for 15O-H2O [9]. The calculated exposure for 
18F-flurpiridaz has initially been estimated in 6.3 mSv [7]. 
Notable, these doses are considerably lower than the ones 
for SPECT perfusion imaging.
The modality of hybrid PET/CT imaging poses an addi-
tional exposure due to the CCTA acquisition (1–18 mSv) 
[10] within the same protocol. Nevertheless, with recent 
improvements in CT technology and the optimization of 
Fig. 2  Acquisition proto-
cols for PET-MPI. Example 
sequence for PET/CT MPI 
with 13N-ammonia, 15O-H2O 
and 82Rb. CT-AC CT-based 
attenuation correction, CaC 
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all-inclusive protocols with physiological tracers and pro-
spectively triggered step-and-shoot CCTA, a full PET/CT 
imaging can currently be performed with a radiation dose 
under 10 mSv [11].
Perfusion radiotracers
Several radiotracers have proved suitable for perform-
ing adequate and reproducible PET MPI. The most com-
monly used are Rubidium-82 (82Rb), Nitrogen-13 ammonia 
(13N-ammonia) and Oxygen-15 labeled water (15O-H2O), 
their general characteristics are summarized in Table 1 panel 
A.
13N-ammonia This radiotracer represents an attractive 
compound with a relatively short half-life (9.96 min) and 
appealing uptake kinetics. 13N-ammonia undergoes a cell-
trapping process due to its conversion to glutamine inside 
the cell. The favorable positron range (2.53 mm) and an 80% 
extraction fraction allow acquisition of intermediate to high-
quality images. The production of 13N-ammonia requires 
an on-site cyclotron, limiting its availability. Nevertheless, 
smaller single-site cyclotrons presently offer unit dose pro-
duction and use for 13N-ammonia [4]. Research on results 
from this production is not yet available.
15O-H2O. 15O-H2O portraits the ideal radiotracer for 
flow quantification due to its free diffusion through the cell 
membrane and proportional tissue uptake to flow. 15O-H2O 
has a physical half-life of 2.06 min and an intermediate 
positron range (4.14 mm). Remarkably, its extraction frac-
tion is 100%. Due to tracer characteristics, visual analysis 
of images is rather inadequate and absolute quantification 
or visualization of parametric images is preferred. Clinical 
research has indeed demonstrated the feasibility and diag-
nostic quality of parametric imaging with 15O-H2O [12]. 
This radiotracer also requires an on-site cyclotron for its 
production and unlike 13N-ammonia, its half-life does not 
allow for nearby distribution.
82Rubidium. 82Rb was one of the first introduced PET 
tracers. Notably, it does not require an on-site cyclotron for 
its production. Instead, 82Rb can be obtained from commer-
cially available elution generators which have a 5-week shelf 
life, but availability has been hindered by limits in 82Stron-
tium production. Presently, it constitutes the most used PET 
perfusion radiotracer in the USA. 82Rb is potassium analog 
with a short physical half-life (76 s) with kinetic properties 
comparable to 201Thallium. It has a lower extraction frac-
tion than other tracers as well as a longer positron range 
(8.6 mm) which limits the resolution of the generated images 
[4]. Nevertheless, due to its versatility, the greatest body of 
evidence and experience has been generated around 82Rb 
perfusion studies.
Nowadays, research efforts have been dedicated to the 
development of new 18Fluorine-based perfusion radiotrac-
ers to attend to the growing need for providing access to 
PET perfusion radiotracers for a greater number of patients. 
18Fluorine-based tracers offer a relatively long half-life of 
110 min. As such, compounds like 18F-flurpiridaz, fluorodi-
hydrorotenone (18F-FDHR) [4] and several iterations of tri-
phenyl phosphonium salts are currently under development.
18F-Flurpiridaz is a structural analog of the insecticide 
pyridaben [13], an inhibitor of the NADH:ubiquinone oxi-
doreductase by competing for binding with ubiquinone 
Table 1  PET perfusion radiotracer characteristics (panel A) and evidence-based status of implementation (panel B)
References in italics are indexed abstracts
13N-ammonia 15O-H2O 82Rubidium 18F-flurpiridaz
A
 Half-life 9.96 min 2.06 min 76 s 109 min
 Positron range (mm) 2.53 4.14 8.6 1.03
 Myocardial extraction 
(%)
80 100 65 94
 Perfusion defect contrast Intermediate Intermediate Lowest Highest
 Cyclotron needed Onsite or nearby Onsite No In the region
B
 Validation Muzik et al. [55], Bol et al. 
[56]
Bergmann et al. [57] Huang et al. [58], Lau-
tamäki et al. [59]
Maddahi et al. [60], Berman 




Nesterov et al.  (2012,), 
Nesterov et al . (2017)
Nesterov et al. [61], Harms 
et al. [62]
Nesterov et al. [19], Kit-
kungvan et al. [63]
 Cut-off exploration Renaud et al. [64] Kajander et al. [50], Danad 
et al. [35]
Renaud et al. [64], Naya 
et al. [34]
 Clinical testing for 
outcomes
Neglia et al. [29], Danad 
et al. [30]
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without affecting the cardiac cell viability. It has demon-
strated a short positron range (1.03 mm) and a high extrac-
tion fraction (94%), offering improved image quality as doc-
umented by phase I and II trials [7]. Quantification over a 
wide range of MBF with 18F-Flurpiridaz has been performed 
with engaging results that have demonstrated sensitive vari-
ations across CAD status [14].
18Fluorine-labeled phosphonium derivates (18F- FATPs) 
have demonstrated potential for PET MPI in preclinical 
studies. 18F- FATPs accumulate in cardiac myocytes due to 
their higher mitochondrial membrane potential and show 
intense myocardial uptake with sharp delineation of perfu-
sion defects in animal models [15]. 18F- FATPs have been 
compared to 13N-ammonia and favorable warrant further 
extension into clinical studies in the coming years [16].
Dedicated software
Several tailored softwares are available for automatic image 
reconstruction and blood flow quantification with mini-
mum observer intervention such as QPS, syngoMBF, 4DM, 
PMOD, EcTB, CARIMAS, FlowQuant, HOQUTO, amongst 
others.
Due to heterogeneity in the models and reconstruction 
software application, recent research has been conducted to 
investigate whether estimations of flow with one or another 
model, software or scanner are to be considered interchange-
able. There is evidence of good agreement between software 
packages for blood flow quantification with 82Rb [17] and 
13N-ammonia [18] studies and it has been stated that recon-
struction using a wide range of software, under the assump-
tion of a 1-tissue compartment mode, has sufficient agree-
ment to be used interchangeably. Nevertheless, it has also 
been demonstrated that agreement is not optimal between 
estimations derived from different kinetic models [19]. In 
summary, the choice of a kinetic model seems to constitute a 
greater influence in the feasibility of MBF comparison than 
the software used. Provided that the kinetic model applied 
will also depend on the used radiotracer, there is an evident 
added level of complexity in the matter.
Since current software alternatives allow quick and 
mostly automated estimations of parameters such as MBF, 
current challenges for software development and utilization 
mostly rely on the impending need for standardization, mod-
els and estimates validation in alternative populations and 
results optimization for attempting data pooling in a larger 
scale.
Quantification of myocardial perfusion
Dynamic acquisitions are used to map the distribution 
and concentration of the radiotracer during rest and stress 
throughout the myocardium by applying tracer kinetic 
models, which account for the influence of partial volume 
effect, spatial resolution, and motion. Usually, a one- or 
two-tissue compartment model is considered and first-pass 
activity distribution (K1 = extraction, which varies across 
tracers showing a roll-off effect at higher blood flows) are 
used to derive global and regional time–activity curves that 
yield estimation of the absolute myocardial blood flow. Fea-
tures that increase the value of such estimations are the high 
temporal resolution of the technique, as well as the compul-
sory correction of photon attenuation. The magnitude of the 
underestimation of MBF at higher values couples with the 
necessary adjustment per tracer, but also increases the uncer-
tainty around the equivalence of the quantification results. 
In this sense, 82Rb conveys the lower extraction value, while 
that of 13N-ammonia is perceivably better (see Perfusion 
radiotracers).
Furthermore, MBF estimations can be corrected to sys-
tematically account for the variability of the rate-pressure 
product (RPP) an index of myocardial oxygen consumption 
[20]. Since the relation between RPP and MBF is decou-
pled during stress, the correction is only made for rest MBF 
[21]. MBF is measured in milliliters per gram of tissue per 
minute (ml/g/min); theoretically, this allows for comparable 
magnitudes across studies and pathologic conditions (see 
Dedicated software).
Stress myocardial blood flow and the ratio between stress 
and rest flow, named myocardial perfusion reserve (MPR), 
are used to evaluate the vasodilatory capacity of the coro-
nary artery tree globally as well as regionally, based on sev-
eral proposed segmentations such as the 17-segment model 
proposed by the American Heart Association or the vessel 
territory segmentation.
Furthermore, it is possible to compare MBF estimations 
obtained during the two or three scan phases. The ratio of 
CPT-MBF to rest MBF is known as the endothelial-depend-
ent vasodilatory index (EDVI), while the ratio of stress 
MBF to rest MBF is known as the coronary flow reserve or 
myocardial perfusion reserve (MPR). Pharmacological or 
exercise stress evokes a compound vascular response and 
is suggested to represent the integrated coronary vascular 
function expressed by MPR.
Several factors exert a direct influence in the coronary 
vasodilator capacity and there is no simple relationship 
between pathologic-morphologic features (from non-inva-
sive or invasive angiography) and perfusion defects. Nota-
bly, stress MBF and MPR have been recognized as impor-
tant physiological parameters of cardiovascular health. 
These measurements have shown an inverse relationship 
with increasing severity of epicardial obstructive CAD and 
stress-induced regional perfusion defects [22]. Nevertheless, 
a marked variability is present across individual patients.
Since quantitative PET merges the perfusion dynamics of 
the main epicardial vessels and the microvascular circulatory 
52 Clinical and Translational Imaging (2018) 6:47–60
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detail in an integrative measurement, abnormal results in this 
evaluation should be carefully considered in accordance to 
factors that may hamper microvascular circulation addition-
ally to flow-limiting subepicardial vessel stenoses. Hybrid 
imaging (PET/CT and PET/MR) has arisen in response 
to this need given the clinical importance of making this 
distinction.
Therefore, quantitative perfusion assessment may result 
useful to identify vasomotor abnormalities preceding overt 
CAD, improve diagnostic accuracy for CAD, estimate the 
burden of the disease in the full extent of the coronary sys-
tem, potentially evaluate the effect of medical interven-
tions, and enhance risk assessment for optimal prognostic 
evaluation.
Diagnostic applications
As for any technique, the pathologic horizon of applications 
of quantitative PET follows the natural history of the dis-
ease of interest (i.e. CAD). Evaluation of initial endothelial 
dysfunction in the microvascular detail and progression to 
non-obstructive and obstructive- or ischemic burden caus-
ing-CAD have been well described. The process of imple-
mentation for such purposes entails validation, agreement, 
threshold-establishing and clinical outcome studies. As such, 
available tracers demonstrate a differential implementation 
moment according to published reports. This is depicted in 
Table 1 panel B (however, references are not meant to be 
exhaustive). The understanding of this state of affairs is para-
mount for clinical investigators in order to advance efforts to 
achieve widespread clinical implementation.
Microvascular disease and treatment monitoring
Through the years, several reports using PET have dem-
onstrated microvascular dysfunction in narrowly selected 
subsets of patients with specific cardiovascular risk factors 
such as smoking [23], dyslipidemia [24], hypertension [25], 
diabetes mellitus [26] and rheumatic diseases [27].
The EDVI and the MPR have been evaluated to detect 
impairment of coronary endothelial function and total vaso-
dilatory function [6], respectively. Results from these stud-
ies suggest that non-invasive evaluation through quantitative 
PET can demonstrate impaired vasomotor function in the 
presence of cardiovascular risk factors. This may serve as a 
pathophysiological proxy of subclinical CAD, which might 
benefit from intense life-style modification.
Noteworthy, some studies have shown improvement 
in MBF dynamics through several interventions and after 
long-term risk factor modification [28]. This evidence sug-
gests that treatment follow-up is feasible through quantita-
tive PET. Nevertheless, doubts regarding the feasibility of 
this approach due to radiation exposure and costs should be 
further addressed. Notably, special patient populations may 
benefit from such an approach considering their morbidity 
profile (autoimmune disorders as vasculitis) and are to be 
contemplated in a patient-to-patient basis.
Identifying and characterizing the burden 
of coronary artery disease
PET has long been known to be an excellent study to detect 
regional myocardial perfusion defects. The clinical signifi-
cance of the coronary lesions may be appropriately assessed 
with the advantage of sparing the patient from subsequent 
potentially unnecessary invasive procedures such as coro-
nary angiography, which are not free of risk.
Currently, PET is considered the quantitative reference 
standard myocardial perfusion and it has demonstrated a 
good performance yielding a sensitivity of 81% and a speci-
ficity of 89% for angiographically significant coronary artery 
stenosis in the recently reported EVINCI trial [29]. Another 
major study, the PACIFIC trial, demonstrated directly that 
15O-H2O PET conveys the best diagnostic performance (in 
comparison to SPECT and CCTA) with a sensitivity of 87% 
and a specificity of 84% for the detection of functionally 
significant lesions evaluated by fractional flow reserve (FFR) 
[30], the current gold standard for the functional assessment 
of coronary stenosis [31]. Figure 3 depicts a typical patient 
with intermediate risk of CAD investigated for myocardial 
ischemia.
Systematic evaluations of the diagnostic performance of 
PET have also been published. In one, Jaarsma et al. demon-
strated an overall 84% sensitivity and 81% specificity across 
15 studies in a per-patient basis considering a ≥ 50% luminal 
stenosis by invasive angiography as the reference standard 
[32]. Another report by Takx et al. documented a sensitiv-
ity and specificity of 84 and 87%, respectively, and 83 and 
89% at the vessel level. Although this study was based on 3 
publications, it adequately utilized FFR as reference stand-
ard [31].
Flow quantification represents an additional feature that 
places PET above other non-invasive techniques in some 
aspects. One of the well-known applications is the scenario 
where perfusion is altered throughout several myocardial 
regions. In this scenario, traditional semi-quantitative 
assessment of PET imaging fails to comprehensively assess 
perfusion abnormalities due to its relative nature, consider-
ing the assumption that the region with the highest perfusion 
represents normality and is, therefore, used as reference.
Global reduction of perfusion can, on the other hand, be 
demonstrated through quantitative measurements, which are 
independent of a reference region. The determination of the 
etiology of the perfusion defect becomes a matter of addi-
tive diagnostic information since distinction form diffuse 
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microvascular disease from multiple subepicardial vessel 
affection is difficult to address considering that also coronary 
abnormalities can play a role in hampering perfusion. As 
an example of the latter, reports of perfusion abnormalities 
are developing around coronary ectasia with and without 
atherosclerotic lesions [33]. The lack of such a distinction 
can lead to falsely negative results and underestimation of 
the cardiac risk in a given patient. In this clinical scenario, 
patients with trivascular involvement who present such a 
“pseudonormalization” phenomenon or “balanced” ischemia 
can be adequately studied with flow quantification (e.g., in 
Fig. 4), although this phenomenon may be less prevalent 
than originally considered.
More commonly, quantitative perfusion aids in the char-
acterization of patients with single-, two- or three-vessel 
disease with a differential in perfusion impairment between 
coronary vessels. While, techniques like SPECT or even 
semi-quantitative analysis with PET may report findings 
compatible with one-vessel CAD, quantification contributes 
with objective measures for the rest of the vessel territories 
providing a comprehensive view on the impact of CAD over 
the coronary circulation (e.g., in Fig. 5). Still, while a pre-
served MPR has shown a very high negative predictive value 
for excluding high-risk CAD, abnormalities in MPR alone 
cannot distinguish the level of the coronary tree affected by 
the suspected CAD [34].
Regional reductions in perfusion may, thus, be due to 
flow-limiting effects of coronary lesions or, as mentioned 
earlier, microvascular dysfunction related to cardiovascu-
lar risk factors, and the discrimination of effects cannot be 
addressed by the measurement alone even though several 
cutoff values have been studied to optimize obstructive CAD 
detection. For instance, the efforts conducted by Danad et al. 
have documented that 2.3 ml/min/g for hyperemic MBF 
Fig. 3  PET MPI. PET MPI study of a 53 year-old patient undergoing 
evaluation for suspected CAD. The study shows moderate ischemia in 
the inferolateral wall (gray arrows), suggestive of left circumflex cor-
onary artery and/or right coronary artery lesion. PET positron emis-
sion tomography, MPI myocardial perfusion imaging, CAD coronary 
artery disease
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and 2.5 for MPR could represent optimal cutoff values for 
regional quantitative 15O-H2O PET [35] in the detection of 
invasive coronary angiography- and FFR-significant CAD 
[36].
Diagnostic performance improvement for CAD has been 
studied with similar results showing improvement in sen-
sitivity and specificity by adding the quantitative evalua-
tion, which in turn, does not require much more effort in 
Fig. 4  MBF Quantification 
in multivessel CAD. PET 
MPI study showing very 
mild ischemic findings in the 
anteroapical and apicolateral 
segments in the semi-quanti-
tative analysis. Nevertheless, 
quantitative assessment shows 
a reduced stress MBF and MPR 
in all arterial territories, achiev-
ing a better characterization of 
the trivascular disease, owing 
to a balanced ischemia or pseu-
donormalization phenomenon. 
MBF myocardial blood flow, 
CAD coronary artery disease, 
PET positron emission tomogra-
phy, MPI myocardial perfusion 
imaging, CFR coronary flow 
reserve/myocardial perfusion 
reserve
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the acquisition protocol making it an attractive technical 
addition (Fig. 3). Studies for establishing the most adequate 
threshold for abnormal stress MBF and MPR have been con-
ducted and current evidence suggests that the former might 
yield a better diagnostic and prognostic value than the latter, 
in the setting of CAD detection [37].
Notably, there has also been information regarding the 
link between perfusion measurement and cardiac function. 
In this sense, it seems that the correlation between stress 
MBF and ventricular function and synchrony is better than 
that of MPR [38]. Further investigations should be encour-
aged to evaluate diagnostic and prognostic utility when par-
allel aspects of function are considered. This could be useful 
in patients in which only stress MBF protocols have been 
performed or prospectively, in patients in which stress-only 
should be performed due to radiation doses concerns.
It is evident then that MBF quantification and derived 
measures are to be considered within the integral PET MPI 
study as added values, which aid and improve the quality 
of the conclusions drawn from it. It has been stated that 
abnormal quantitative measurements are to be interpreted 
in addition to parallel anatomic and functional assessments 
to complement the information obtained and pinpoint the 
best way to proceed into the therapeutic process. It is here 
where hybrid modalities emerge and offer the added value 
of complementary anatomical and functional information. 
Whether its utilization will lead to improved patient out-
comes is still to be answered. The essence of quantification 
as a “gatekeeper” for cardiac catheterization should strive 
for, in turn, moderating revascularization procedures.
In this way, the added value of flow quantification has 
expanded the possibilities of the technique from basic detec-
tion of advanced flow-limiting epicardial CAD to the broad 
evaluation of subclinical disease, the better characterization 
of its burden and the unmasking of multivessel perfusion 
affection.
It is relevant to circle back to the fact that different trac-
ers currently exhibit different amount of evidence regard-
ing their implementation, and that currently, although 
13N-ammonia and 82Rb are used for clinical purposes, only 
data on the full diagnostic validation path for 15O-H2O is 
available.
Fig. 5  Quantitative PET/CT (hybrid) in suspected CAD. PET MPI 
study showing severe semi-quantitative ischemia in the inferior ven-
tricular wall, suggestive of RCA involvement. Nevertheless, quanti-
tative assessment shows a reduced stress MBF (0.90  ml/g/min) and 
MPR (2.23) in the same territory in comparison to the rest of the ven-
tricular walls. CCTA documented non-calcified plaques with proxi-
mal RCA ectasia (7 mm)
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Risk evaluation and prognostic performance
Recently, clinical research has been trying to address another 
critical aspect of cardiac PET/CT application: whether its 
prognostic yield is relevant in comparison with more acces-
sible techniques.
It has been shown that when applying the most common 
indications for PET MPI, which include chest pain, dysp-
nea or both, roughly half of the studies can be classified as 
normal according to the semi-quantitative visual analysis. 
Furthermore, with the possibility of measuring the MBF 
in absolute terms, recent studies have shown the correla-
tion and incremental prognostic utility and added value of 
MPR measurements in the mid- and long-term follow-up, 
even after revascularization procedures [39]. Short-term 
follow-up studies have evaluated MPR as a relevant marker 
for prediction of cardiovascular events even within the sub-
group of patients without regional perfusion abnormalities 
and previously infarcted patients. This supports the notion 
that MPR can be considered as an integrative marker for CV 
risk independent of previous CV events.
At the same time, the non-invasive measurement of MPR 
has been able to identify patients at increased risk of car-
diac mortality in that a preserved MPR (≥ 2.0) conveys an 
extremely low rate of cardiac mortality in contrast to patients 
with severely reduced MPR (hazard ratio of 5.6), even sug-
gesting a “3-year warranty” event-free period. Moreover, 
MPR has shown utility in patient risk reclassification within 
the intermediate cardiovascular risk population (up to one 
third), which may constitute a major advantage for the 
technique considering that quantitative evaluation of MBF 
through PET MPI does not bear additional costs, procedures 
or radiation exposure. Additionally, PET MPI also results 
advantageous in the stress study of high-risk subsets of 
patients such as those with heart failure and obesity [40].
In the absence of epicardial stenosis, a decreased MPR is 
considered to document microvascular dysfunction caused 
by traditional CV risk factors, reflecting an early stage within 
the CAD horizon, while a preserved MPR portrays an excel-
lent mid-term prognosis in patients with otherwise common 
risk factors. Moreover, quantitative PET MPI abnormalities 
have demonstrated to predict heart failure outcomes [41], 
and MPR has been evaluated as a stronger predictor for car-
diac death than left ventricle ejection fraction [42].
Recently, this information has been systematically 
reviewed by our group—Juarez-Orozco and colleagues—
to lay out and compare the reported prognostic significance 
of PET perfusion estimations [43]. We have concluded that 
perfusion estimations hold robust prognostic performance 
but only for the occurrence of major adverse CV events, 
while there is still a paucity of information regarding the 
occurrence of cardiac death alone. A directional com-
parison showed that MPR could be a better independent 
prognostic factor per se than stress MBF. Notably, this 
report underlines the substantial heterogeneity across stud-
ies, which represents a target for future development and 
standardization. Within the gathered studies, the report by 
Gupta et al. [44] assessed the differential significance and 
additive prognostic value of perfusion estimations (i.e., 
stress MBF and MPR). It seems then, that a concordantly 
hampered reduction in both estimations shows the high-
est association with cardiovascular mortality. Moreover, 
they reported that a preserved MPR can classify low-risk 
patients even when stress MBF is affected. This large 
report used mainly estimations provided by 82Rb quan-
tification and 13N-ammonia in a minority of patients, a 
feature that raises the concern of the error introduced by 
conceding the exchangeability of estimations from differ-
ent tracers.
Importantly, their results should be considered within 
the context of global perfusion measurements because in 
contrast, the evaluated study by Maaniitty et al. [45] has 
documented the prognostic value of regional stress MBF 
in the sequential application of coronary computed tomog-
raphy angiography (CCTA) and 15O-H2O PET supporting 
its robustness and applicability.
An additional concern raise by our systematic investiga-
tion is that the prognostic value of a technique, particularly 
in cardiovascular medicine, must be understood from the 
operationalization of outcomes of interest. As suspected, 
profound differences were found in the amount and type of 
events recorded as MACEs, which contributed to hamper 
the potential pooling of reported results.
Finally, a recent report by Smulders et al. addressed the 
prognostic value of a negative result in non-invasive imag-
ing with several techniques (including PET) concluding 
that overall, such a result conveys excellent prognosis in 
known or suspected CAD [46].
Findings from this type of studies may be valuable in 
determining which patients could be adequately selected 
for medical treatment alone and which would need further 
testing or interventional procedures to improve mortal-
ity rates. Moreover, it is likely that quantitative perfusion 
evaluation through PET could aid in treatment monitor-
ing (for both primary and secondary prevention) since the 
intrinsic prognostic value of MBF and MFR is robustly 
documented. For instance, Schindler et al. documented the 
improvement in vascular reactivity as measured by quanti-
tative perfusion in diabetic patients subjected to glucose-
lowering treatment [47]. Also, Quercoli et al. have dem-
onstrated an improvement in coronary vasomotor function 
(both during CPT and pharmacological stress) after gas-
tric-bypass in morbidly obese subjects [48]. However, 
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whether vasomotor function can constitute a robust target 
for risk modification remains to be tested.
Furthermore, recent studies are unequivocally shift-
ing towards the inclusion of enriched and geographically 
diverse groups of patients in an attempt to enhance the 
generalizable implications of its results.
Hybrid modalities
Nowadays, most of the available centers for PET scan-
ning utilize it in the form of hybrid equipment, mostly in 
combination with CT scan (PET/CT), and in a much more 
discreet, but growing degree, with MRI (PET/MRI).
This is important because PET/CT provides comple-
mentary information. On one side, it documents the evalu-
ation of intrinsic physiological and functional processes 
through PET (depending on the selected radiotracer and 
quantitative analysis) and on the other side, it delivers an 
accurate anatomical evaluation of the heart, the coronary 
vessels and related structures. This allows us to frame a 
comprehensive image of the disease, compensating for 
each technique’s individual drawbacks at the same time 
[49].
The addition of CCTA and coronary calcium scor-
ing helps to clarify the etiology of the perfusion defects, 
which could be attributed to flow-limiting lesions, unex-
pected artifacts, or false positive results (inherent to 
every technique). This is due to the ability of contrast-
enhanced CCTA to directly characterize coronary stenosis 
and plaque gross structure. CCTA has established itself 
as a useful method in the clinical scenario for resolving 
unclear PET MPI results, defining multivessel disease in 
“at glance” normal perfusion studies and excluding sig-
nificant CAD in low and intermediate cardiovascular risk 
patients [50].
Several studies have shown improved sensitivity, spec-
ificity and accuracy of hybrid PET/CT over each study 
alone for the diagnosis of clinically significant CAD [37]. 
Furthermore, the information provided can support or 
discourage unnecessary invasive angiographic assess-
ments and has demonstrated value in risk stratification 
and prognosis [51]. Although a diagnostic approach in 
which CCTA is performed to exclude significant CAD 
and spare MPI has proven to be cost effective and to avoid 
an increase in utilization of other imaging methods [52], 
the increasingly evolving notion of benefit from comple-
mentary information from hybrid methods is evident as 
exemplified in Fig. 5.
The theoretical advantages of such technical features 
of hybrid modalities converge in the improved evalua-
tion of subclinical and overt CAD and in the determina-
tion of early pathophysiological changes of the disease 
(intermediate risk) as well as complex disease in patients 
with long-standing CV disease features (multivessel dis-
ease with complex anatomy or chronic occlusions). How-
ever, this is stance is now without controversy. In fact 
recently, the results from the PACIFIC trial showed that 
hybrid modalities’ performance was not superior to that 
of individual techniques in the detection of functionally 
significant CAD [30] (besides demonstrating that PET 
conveys the best diagnostic performance overall). As 
such, open questions remain concerning hybrid technique 
application and whether the term itself represents the 
simultaneous use of individual techniques, the utility of 
concordant results for individual techniques or the sequen-
tial interpretation when two techniques are performed. In 
this last regard, a recent study by Maaniitty et al. [45] has 
documented the prognostic utility of a selective sequen-
tial application of 15O-H2O PET when evaluating dubi-
ous or positive CT angiography results. Their results have 
shown that the mortality rate for patients with CT-obstruc-
tive CAD but without ischemia is comparable to that of 
patients in whom obstructive CAD has been excluded.
Nowadays, PET/MR scanners offer attractive possibili-
ties for combining measures of ventricular function, perfu-
sion, viability, and infarct scar for evaluation of ischemic 
heart disease due to the intrinsic advantages of MR (no 
radiation exposure and higher spatial resolution). Then 
again, complementary value of PET/MR has to be dem-
onstrated above the overlapping nature of the information 
provided. It has been stated that the greater contribution 
of PET/MR in the realm of cardiovascular disease will 
crystallize beyond CAD evaluation, for example, in the 
characterization of cardiomyopathies or infiltrative dis-
eases [53].
In the clinical scenario, hybrid imaging could be justified 
according to the clinical question for the individual patients 
and the need for physiological data and precise anatomic 
delineation must be considered a feasible advantage of the 
equipment more than an automatic choice linked to the pos-
sibility of obtaining additional information [54].
Conclusion
PET myocardial perfusion currently represents the reference 
technique for quantitative perfusion assessment. The contri-
bution of MBF and MPR beyond traditional semiquantitative 
evaluation of perfusion abnormalities improves diagnostic 
and prognostic performance in patients with CAD. Quanti-
fication of MBF with PET allows detection of early vasomo-
tor abnormalities linked to subclinical disease; it permits 
treatment evaluation and it offers accurate diagnostic evalu-
ation of patients with known or suspected atherosclerosis. 
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Additionally, its prognostic value is steadily being recog-
nized. New developments in available tracers and hybrid 
modalities will enhance the possibilities of accurate non-
invasive imaging in several clinical scenarios. Therefore, 
the clinical value of PET quantitative perfusion is expected 
to improve patient outcomes and optimize therapeutic deci-
sions, which constitute key elements for the future of car-
diovascular medicine.
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